The use of high-dose therapy (HDT) has improved the outcome of younger patients with multiple myeloma (MM). 1 Further advance in this procedure was achieved in the 1990s when mobilized PBSC were proposed to perform autologous stem cell transplantation (ASCT) instead of bone marrow, 2, 3 inducing faster hematopoietic recovery. However, both types of grafts contain plasma cells (PC) and, potentially, tumor PC (tPC), thus being liable to induce relapse after ASCT. Several techniques have been used to detect these remaining PC, such as PCR, 4 M-protein detection 4 or flow cytometry. 5 In the late 1990s, following the induction regimen based on VCR, doxorubicin and dexamethasone (VAD regimen), the levels of residual PC have been shown to be around 1.5 × 10 5 /kg, even reaching 10 9 per transplant according to Lemoli et al. 6 This tumor cell contamination has also been described as a prognostic factor for outcome in some series. 5 In recent years, the outcome of MM patients has further improved with the incorporation of novel agents such as proteasome inhibitors (PI) and immunomodulatory drugs (IMiDs). 7 Standard regimens prior to ASCT have been modified over the last decade, and triplet combinations including one PI +one IMiD+dexamethasone are considered to be the best options to induce high response rates before HDT. 8 However, little is known of the efficacy of these new combinations in efficiently reducing the number of residual tPC contaminating the graft of PBSC. It is expected that these tumor cell numbers will be very low, and recent techniques of multiparameter flow cytometry can be applied to their detection. Indeed, such methods are used for the assessment of minimal residual disease (MRD), after treatment and ASCT. 9, 10 Here, we report on a prospective study aimed at evaluating both PC and tPC contamination of ASCT grafts after induction therapy with current frontline induction strategies. Apheresis products were evaluated by flow cytometry before and after cryopreservation, that is, following the stem cell harvest and whenever available before reinfusion post conditioning regimen.
This single-center prospective study was carried out between 02/2013 and 09/2014. Forty-three consecutive patients with symptomatic MM, median age 60 years old (range 39-67), treated with frontline ASCT, were enrolled. All patients received 3-4 cycles (median 4) of an induction regimen that consisted of triplet PI+IMiD+dexamethasone-based therapy as shown in Table 1a . Stem cell harvest was performed following cyclophosphamide and G-CSF mobilization after cycle 3. Stem cell collection was successful for all patients who subsequently received high-dose melphalan (200 mg/m 2 ) followed by ASCT. Responses following induction treatment and ASCT were evaluated according to the International Myeloma Working Group (IMWG) criteria. Abbreviations: CR = complete response; F = female; HDT/ASCT = high-dose therapy/auto-SCT; ISS = International Staging System; KRD = carfilzomib, revlimid, dexamethasone; M = male; NA = not available; PR = partial response; SD = stable disease; VCD = bortezomib, cyclophosphamide, dexamethasone; VGPR = very good partial response; VTD = bortezomib, thalidomide, dexamethasone.
elsewhere. 12 Acquisition was performed on a Canto II (BDBiosciences) flow cytometer and the analysis of all PC subsets were carried out as reported. 12 Three variables were collected: the percentage of total PC ((number of PC/number of total nucleated cells) × 100), percentage of normal (polyclonal) PC among total PC and percentage of tPC among total PC. χ 2 and paired Student's t-tests were used to compare the percentages of cells before and after apheresis cryopreservation. Statistical significance was considered for P-values o0.05. PFS was compared between patients with or without tPC in the apheresis product by the log-rank test and Kaplan-Meier curves. All statistical tests were performed using MedCalc (Ostend, Belgium).
Detailed results of the PC counts are given in Tables 1b and c ). After thawing, at the time of ASCT, the median number of total PC was 4 × 10 − 4 (range 0.1-337.5 × 10 − 4 ). Paired analysis of the 22 samples tested before and after thawing showed no statistical difference regarding PC contamination (P = 0.32). Among these PC, the median value of normal polyclonal PC was 100% in both types of samples. The median of tPC was 0, Abbreviations: CR = complete response; HDT/ASCT = high-dose therapy/auto-SCT; nPC = normal plasma cells; PR = partial response; SD = stable disease; tPC = tumoral plasma cells; VGPR = very good partial response; 0 = absence of relapse; 1 = relapse.
yet, tPC were detectable in 10 of the 43 samples (23%) at the time of collection (range 0.05-76.4% of total PC) and in 4 of the 22 samples (18%) at the time of reinfusion (range 18-50.5% of total PC). This difference was not statistically significant (P = 0.7) and demonstrates the absence of deleterious effect of the storage and thawing procedure, which preserves the composition of apheresis products. This study confirms the efficacy of the single-tube, seven-color flow cytometry strategy to detect rare events in cell samples. 12 Of note, because it uses not only immunophenotypic aberrancies (such as CD19 loss or acquisition of CD56 and/or CD28), but also the intracytoplasmic expression of Ig light chains, this method allows for an accurate evaluation of both normal and tPC. This is at variance with data from the study of Kopp et al. 5 in 2009, where only total PC were enumerated using the single combination of CD38 and CD138. This work also demonstrates the feasibility of this dichotomic evaluation in apheresis samples.
The overall response rate to induction therapy was 95% (two patients remained in stable disease) including 7% CR, 63% VGPR and 25% PR. Following ASCT, the CR rate increased up to 33% (Table 1a ). The 10 patients with tPC detectable in the apheresis product ultimately reached CR (N = 1), VGPR (N = 5) or PR (N = 3) whereas one remained with a stable disease. During the median of 15 months follow-up (range 11-25 months), 13 relapses occurred (30%). The median PFS of patients for whom residual tPC were observed in the apheresis sample was 16 months (95% confidence interval 13-17, but was not reached for those without tPC (P = 0.008, Figure 1) ). Of note, this study shows that the high response rate achieved with triplet induction regimens prior to ASCT is associated with good clearance of tPC within the PBSC graft, as compared with the indisputable graft contamination that was almost systematically described 10 to 15 years ago with the VAD regimen. It is of interest to note that median levels of normal PC were at 100% and median levels of tPC were at 0% in apheresis collections. However, the proportions of detectable tPC were not affected by cryopreservation, confirming that normal and tPC have the same behavior after thawing. Overall, the majority of patients had no tPC contaminating their graft following four cycles of VTD (bortezomib, thalidomide, dexamethasone) or VCD (bortezomib, cyclophosphamide, dexamethasone) induction regimen. Nevertheless, PFS data show that the rate of progression was higher in the group of patients with detectable tPC in the apheresis product, suggesting a potentially deleterious role for these cells. This has to be interpreted cautiously, as initial characteristics, induction regimens and post-ASCT therapies were not identical when comparing the two groups of patients with or without tPC. Data from this study require to be confirmed in a larger prospective study including patients treated homogeneously.
